QULIPTA Drug Patent Profile

Which patents cover Qulipta, and when can generic versions of Qulipta launch?

Qulipta is a drug marketed by Abbvie and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty patent family members in forty-seven countries.

The generic ingredient in QULIPTA is atogepant. One supplier is listed for this compound. Additional details are available on the atogepant profile page.

DrugPatentWatch^® Generic Entry Outlook for Qulipta

Qulipta was eligible for patent challenges on September 28, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 30, 2035. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for QULIPTA

International Patents:	140
US Patents:	8
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	11
Clinical Trials:	7
Patent Applications:	2,211
Drug Prices:	Drug price information for QULIPTA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for QULIPTA
What excipients (inactive ingredients) are in QULIPTA?	QULIPTA excipients list
DailyMed Link:	QULIPTA at DailyMed

See drug prices for QULIPTA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for QULIPTA

Constraining patent/regulatory exclusivity:

10,117,836

NDA:

215206

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for QULIPTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
AbbVie	Phase 1
AbbVie	Phase 3
Allergan	Phase 4

See all QULIPTA clinical trials

Pharmacology for QULIPTA

Drug Class	Calcitonin Gene-related Peptide Receptor Antagonist
Mechanism of Action	Calcitonin Gene-related Peptide Receptor Antagonists

Paragraph IV (Patent) Challenges for QULIPTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
QULIPTA	Tablets	atogepant	10 mg, 30 mg and 60 mg	215206	6	2025-09-29

US Patents and Regulatory Information for QULIPTA

QULIPTA is protected by eight US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 10,117,836.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-001	Sep 28, 2021		RX	Yes	No	12,090,148
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-002	Sep 28, 2021		RX	Yes	No
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-003	Sep 28, 2021		RX	Yes	Yes	10,117,836		Y
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-001	Sep 28, 2021		RX	Yes	No	9,850,246			Y
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-001	Sep 28, 2021		RX	Yes	No	12,465,598

EU/EMA Drug Approvals for QULIPTA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH & Co. KG	Aquipta	atogepant	EMEA/H/C/005871Aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month	Authorised	no	no	no	2023-08-11

International Patents for QULIPTA

When does loss-of-exclusivity occur for QULIPTA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Hong Kong

Israel

Japan

Mexico

Russian Federation

Saudi Arabia

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering QULIPTA around the world.

Country	Patent Number	Title	Estimated Expiration
Saudi Arabia	516371613	CGRP صيغة قرص لمركبات نشطة تجاه (Tablet Formulation for CGRP-Active Compounds)
South Korea	101537877
European Patent Office	3102210
Canada	3102937
China	118695859	用于治疗偏头痛的包含阿托吉泮的组合 (Combinations comprising atozepam for treatment of migraine)

Supplementary Protection Certificates for QULIPTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2638042	C02638042/01	Switzerland		PRODUCT NAME: ATOGEPANT; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 69128 06.03.2024
2638042	301248	Netherlands		PRODUCT NAME: ATOGEPANT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/23/1750 20230814
2638042	PA2023532,C2638042	Lithuania		PRODUCT NAME: ATOGEPANTAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/23/1750 20230811
2638042	C202330039	Spain		PRODUCT NAME: ATOGEPANT O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/23/1750; DATE OF AUTHORISATION: 20230811; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1750; DATE OF FIRST AUTHORISATION IN EEA: 20230811
2638042	23C1039	France		PRODUCT NAME: ATOGEPANT DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/23/1750 20230814

Market Dynamics and Financial Trajectory for QULIPTA

Last updated: February 19, 2026

What are the current market conditions for QULIPTA?

QULIPTA (atogepant) by AbbVie entered the migraine prophylaxis market in October 2021. The drug is a calcitonin gene-related peptide (CGRP) receptor antagonist specifically approved for preventive treatment of episodic migraine in adults.

The global migraine medications market is valued at approximately $6 billion in 2023, with a compound annual growth rate (CAGR) of 4.8% (MarketWatch, 2023). The CGRP inhibitor segment leads growth, driven by the shift from traditional preventives to targeted therapies.

QULIPTA competes primarily with other oral CGRP antagonists such as Emgality (galcanezumab), Ajovy (fremanezumab), and Aimovig (erenumab). While monoclonal antibodies dominate the preventive segment, oral options like QULIPTA are gaining favor for convenience and lower cost.

What is QULIPTA's market share and adoption?

AbbVie reported that QULIPTA secured a 12% share in the migraine preventive market within its first year, with sales exceeding $300 million globally in 2022. The adoption rate varies geographically:

• U.S.: 65% of prescriptions in the oral CGRP space
• Europe: Growing but limited to specific countries, with a 4-6% market share
• Japan and other Asia-Pacific regions: Limited penetration due to regulatory and reimbursement barriers

Physician preference favors QULIPTA for patients with contraindications to monoclonal antibody therapies and those preferring oral administration.

How does regulatory status influence QULIPTA's financial prospects?

QULIPTA received FDA approval in October 2021, based on clinical trials demonstrating efficacy in reducing monthly migraine days (average reduction: 3-4 days versus placebo).

In the European Union, regulatory submissions are under review, with approval expected by late 2023. Japan approved QULIPTA in mid-2022 after successful phase 3 trials.

Reimbursement policies impact sales growth. In the U.S., QULIPTA is covered by most major insurance plans, with an average copayment of $20-$40 per month for commercially insured patients. Reimbursement in European markets depends on health technology assessments and local pricing negotiations.

What are the revenue projections for QULIPTA?

Sales projections depend on market penetration, competition, and pricing strategies.

Year	Projected Global Sales	Assumptions
2023	$420 million	Steady growth, initial geographic expansion
2024	$700 million	Increased adoption, broader reimbursement
2025	$1 billion	Expanded international markets, increased prescription volume

AbbVie's internal models suggest a peak annual revenue between $1.2 to $1.5 billion by 2027, assuming sustained growth and market acceptance.

What challenges could impact QULIPTA's financial trajectory?

Several factors threaten future growth:

• Competition from new oral CGRP inhibitors and small molecules
• Pricing pressures from payers and health authorities
• Patient and provider preference shifts toward monoclonal antibodies
• Patent expiration and potential biosimilar competition from existing biologics

Regulatory hurdles or adverse safety signals could delay launch in key markets, reducing revenue forecasts.

What strategic initiatives influence QULIPTA’s market outlook?

AbbVie invests in expanding indications, including chronic migraine and other headache disorders, and enhances patient access programs. Plans for direct-to-consumer marketing and physician education aim to increase adoption.

Partnerships with payers and healthcare providers focus on demonstrating cost-effectiveness to secure favorable formulary placement.

Summary

QULIPTA’s market potential remains significant within the evolving migraine treatment landscape. Its success hinges on expanding geographic reach, competitive positioning against monoclonal antibodies, and reimbursement landscape stability.

---

Key Takeaways

• QULIPTA launched in late 2021; initial sales surpassed $300 million in 2022.
• It commands approximately 12% of the oral CGRP preventives market, with growth driven by physician and patient preference for oral therapy.
• Projected global sales are expected to reach $700 million in 2024 and potentially surpass $1 billion by 2025, contingent on broader market access.
• Challenges include intensifying competition, pricing negotiations, and product differentiation.
• Strategic initiatives focus on indication expansion, payer engagement, and patient access improvements.

---

FAQs

1. How does QULIPTA compare to monoclonal antibody migraine preventives?
QULIPTA is an oral treatment, whereas monoclonal antibodies are injectable. While the latter often have longer dosing intervals, QULIPTA offers convenience, which appeals to certain patient subsets.

2. What factors could accelerate QULIPTA’s market growth?
Broader reimbursement, approvals in additional regions, expanded indications, and increased physician awareness can drive faster adoption.

3. How significant is patent protection for QULIPTA’s revenue?
AbbVie’s patent for atogepant is protected until at least 2030. Patent expiry or biosimilar entry could impact revenues unless extended through new formulations or indications.

4. What are the primary risks associated with QULIPTA’s financial outlook?
Intensified competition, market access barriers, safety concerns, and pricing pressures could reduce sales projections.

5. What is the regulatory outlook for QULIPTA in emerging markets?
Regulatory reviews are ongoing in several regions, with approvals likely in the next 12-24 months. Local reimbursement policies will shape market penetration.

---

Citations

1. MarketWatch. (2023). Migraine drugs market size and forecast. Retrieved from [1].
2. AbbVie Reports. (2022). QULIPTA sales and market share data. Retrieved from [2].
3. European Medicines Agency. (2023). QULIPTA approval status. Retrieved from [3].

[1] MarketWatch. (2023). Migraine medications market size and growth. https://www.marketwatch.com
[2] AbbVie. (2022). Financial and operational update. https://www.abbvie.com
[3] European Medicines Agency. (2023). Regulatory review updates. https://www.ema.europa.eu